n-methylpiperidine has been researched along with 1-(3-(5-(1,2,4-triazol-4-yl)-1h-indol-3-yl)propyl)-4-(2-(3-fluorophenyl)ethyl)piperazine in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Beer, MS; Broughton, HB; Castro, JL; Cheng, SK; Collins, I; Goodacre, SC; Heald, A; Locker, KL; MacLeod, AM; Morrison, D; Moyes, CR; O'Connor, D; Pike, A; Rowley, M; Russell, MG; Sohal, B; Stanton, JA; Thomas, S; van Niel, MB; Verrier, H; Watt, AP | 1 |
1 other study(ies) available for n-methylpiperidine and 1-(3-(5-(1,2,4-triazol-4-yl)-1h-indol-3-yl)propyl)-4-(2-(3-fluorophenyl)ethyl)piperazine
Article | Year |
---|---|
Fluorination of 3-(3-(piperidin-1-yl)propyl)indoles and 3-(3-(piperazin-1-yl)propyl)indoles gives selective human 5-HT1D receptor ligands with improved pharmacokinetic profiles.
Topics: Administration, Oral; Animals; CHO Cells; Cricetinae; Fluorine Compounds; Humans; Indoles; Ligands; Male; Models, Molecular; Piperidines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Structure-Activity Relationship | 1999 |